9-5126542-T-G
Variant names:
Variant summary
Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_004972.4(JAK2):c.3291+96T>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0163 in 977,320 control chromosomes in the GnomAD database, including 1,639 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.066 ( 1071 hom., cov: 32)
Exomes 𝑓: 0.0072 ( 568 hom. )
Consequence
JAK2
NM_004972.4 intron
NM_004972.4 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: 0.240
Publications
2 publications found
Genes affected
JAK2 (HGNC:6192): (Janus kinase 2) This gene encodes a non-receptor tyrosine kinase that plays a central role in cytokine and growth factor signalling. The primary isoform of this protein has an N-terminal FERM domain that is required for erythropoietin receptor association, an SH2 domain that binds STAT transcription factors, a pseudokinase domain and a C-terminal tyrosine kinase domain. Cytokine binding induces autophosphorylation and activation of this kinase. This kinase then recruits and phosphorylates signal transducer and activator of transcription (STAT) proteins. Growth factors like TGF-beta 1 also induce phosphorylation and activation of this kinase and translocation of downstream STAT proteins to the nucleus where they influence gene transcription. Mutations in this gene are associated with numerous inflammatory diseases and malignancies. This gene is a downstream target of the pleiotropic cytokine IL6 that is produced by B cells, T cells, dendritic cells and macrophages to produce an immune response or inflammation. Disregulation of the IL6/JAK2/STAT3 signalling pathways produces increased cellular proliferation and myeloproliferative neoplasms of hematopoietic stem cells. A nonsynonymous mutation in the pseudokinase domain of this gene disrupts the domains inhibitory effect and results in constitutive tyrosine phosphorylation activity and hypersensitivity to cytokine signalling. This gene and the IL6/JAK2/STAT3 signalling pathway is a therapeutic target for the treatment of excessive inflammatory responses to viral infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]
INSL6 (HGNC:6089): (insulin like 6) The protein encoded by this gene contains a classical signature of the insulin superfamily and is significantly similar to relaxin and relaxin-like factor. This gene is preferentially expressed in testis. Its expression in testis is restricted to interstitial cells surrounding seminiferous tubules, which suggests a role in sperm development and fertilization. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -20 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.84).
BP6
Variant 9-5126542-T-G is Benign according to our data. Variant chr9-5126542-T-G is described in ClinVar as [Benign]. Clinvar id is 1240578.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.225 is higher than 0.05.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
JAK2 | ENST00000381652.4 | c.3291+96T>G | intron_variant | Intron 24 of 24 | 1 | NM_004972.4 | ENSP00000371067.4 | |||
INSL6 | ENST00000649639.1 | c.*11-2031A>C | intron_variant | Intron 3 of 3 | ENSP00000497955.1 | |||||
JAK2 | ENST00000487310.1 | n.482+96T>G | intron_variant | Intron 1 of 1 | 2 |
Frequencies
GnomAD3 genomes AF: 0.0657 AC: 9963AN: 151628Hom.: 1066 Cov.: 32 show subpopulations
GnomAD3 genomes
AF:
AC:
9963
AN:
151628
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.00721 AC: 5951AN: 825574Hom.: 568 Cov.: 11 AF XY: 0.00607 AC XY: 2591AN XY: 426598 show subpopulations
GnomAD4 exome
AF:
AC:
5951
AN:
825574
Hom.:
Cov.:
11
AF XY:
AC XY:
2591
AN XY:
426598
show subpopulations
African (AFR)
AF:
AC:
4503
AN:
18994
American (AMR)
AF:
AC:
401
AN:
30200
Ashkenazi Jewish (ASJ)
AF:
AC:
7
AN:
18652
East Asian (EAS)
AF:
AC:
0
AN:
34346
South Asian (SAS)
AF:
AC:
51
AN:
60716
European-Finnish (FIN)
AF:
AC:
0
AN:
47902
Middle Eastern (MID)
AF:
AC:
54
AN:
4396
European-Non Finnish (NFE)
AF:
AC:
315
AN:
571594
Other (OTH)
AF:
AC:
620
AN:
38774
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.510
Heterozygous variant carriers
0
258
516
774
1032
1290
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
GnomAD4 genome AF: 0.0658 AC: 9986AN: 151746Hom.: 1071 Cov.: 32 AF XY: 0.0639 AC XY: 4742AN XY: 74224 show subpopulations
GnomAD4 genome
AF:
AC:
9986
AN:
151746
Hom.:
Cov.:
32
AF XY:
AC XY:
4742
AN XY:
74224
show subpopulations
African (AFR)
AF:
AC:
9474
AN:
41460
American (AMR)
AF:
AC:
370
AN:
15244
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
3456
East Asian (EAS)
AF:
AC:
1
AN:
5188
South Asian (SAS)
AF:
AC:
2
AN:
4820
European-Finnish (FIN)
AF:
AC:
0
AN:
10622
Middle Eastern (MID)
AF:
AC:
3
AN:
294
European-Non Finnish (NFE)
AF:
AC:
49
AN:
67638
Other (OTH)
AF:
AC:
87
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
392
785
1177
1570
1962
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
35
AN:
3478
ClinVar
Significance: Benign
Submissions summary: Benign:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided
- -
Jun 20, 2021
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.